List view / Grid view
In this article, Alison Bourke, Scientific Director of the Center for Advanced Evidence Generation at IQVIA Health, explores how digitally-connected active and passive data sources are shaping the development of patient-centric treatments and care.
A novel algorithm shows that there is a robust network for transferring plasmids between bacteria which may be causing the rapid spread of antibiotic resistance.
The first patient with COVID-19 has been administered agenT-797, an allogeneic cell therapy made by Agenus Inc.
![Phone screen displaying PerkinElmer logo next to a laptop keyboard [Credit: rafapress / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PerkinElmer-3-300x278.jpg)
![Phone screen displaying PerkinElmer logo next to a laptop keyboard [Credit: rafapress / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/PerkinElmer-3-scaled-e1604320818816.jpg)
PerkinElmer will expand its automated life sciences discovery and applied genomics solutions with the acquisition.
The UK’s Health and Social Secretary has launched a new healthcare strategy based on harnessing the potential of advanced genome sequencing for both research and clinical purposes.
In this article Pramod Kumar, a Senior Research Analyst (Healthcare) at P&S Intelligence, explores how single-cell analysis techniques are used for both pharmaceutical R&D and clinical, diagnostic applications.
The European Commission and European Medicines Agency have approved the triple combination Kaftrio for use in certain cystic fibrosis patients, triggering the drug to be accessible on the UK’s National Health Service.
Earlier this year, MGC Pharmaceuticals, in collaboration with the Slovenian National Institute of Biology (NIB) and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia, announced successful research results for their novel cannabinoid formulation, which has been developed for the treatment of glioblastoma. This article highlights the key…
Tofersen reduced expression of the SOD1 gene known to cause amyotrophic lateral sclerosis (ALS) and slowed clinical decline in the Phase I/II trial.
The genomic research platform will initially be used to help fast-track COVID-19 drug research and development, before being leveraged against other diseases, such as cancer.
The European Medicines Agency's human medicines committee (CHMP) said the treatment would offer a therapeutic option for certain cystic fibrosis phenotypes that are currently untreatable.
The UK MRC and LifeArc are making £16 million available as grants to fund the establishment of Gene Therapy Innovation Hubs to improve resources for researchers and manufacturers.
A team have developed a biosensor with high specificity and sensitivity for COVID-19 that could be used in hospitals, train stations or laboratories to detect SARS-CoV-2.
According to researchers, Zolgensma, made by Novartis, will lead the global spinal muscular atrophy market and generate billions in sales.
FLT190 gene therapy has been granted Orphan Drug Designation based on preliminary trial data and the positive opinion of an EMA committee.
